Insurance restrictions that delay or deny access to migraine medication are creating serious healthcare consequences, including increased emergency department visits and hospitalizations. A comprehensive new study has revealed that payer blocking strategies such as step therapy and prior authorization predominantly affect vulnerable populations, particularly those with lower incomes and education levels. These findings highlight a critical gap between available effective treatments and patient access to care, raising urgent questions about healthcare equity and the real-world impact of insurance barriers on migraine management.
Study Reveals Widespread Insurance Denials
Denial Rates Across Healthcare Payers
The research analyzed data from 1,290 managed care organizations and payers, uncovering dramatic variations in how different insurance companies handle migraine medication requests. Denial rates for branded migraine therapies ranged from 0% to an alarming 66%, demonstrating inconsistent standards across the healthcare insurance landscape. This wide variation suggests that access to migraine treatment depends heavily on which insurance plan a patient has, rather than medical necessity or clinical guidelines.
The observational cohort study examined claims from 370,560 migraine patients who received treatment between January 2019 and December 2021. These patients were prescribed branded acute and preventive medications, representing real-world treatment patterns. Data sources included electronic health records, emergency department visit documentation, specialty pharmacy records, and in-office dispensing information.
Demographics Most Affected
The study revealed concerning disparities in who faces insurance barriers for migraine treatment. Payer blocking affected approximately one in five patients, with higher rates among individuals with lower income and education levels. The analysis also identified variations by race and ethnicity, with all differences reaching statistical significance, though effect sizes were relatively small. These findings suggest that insurance restrictions may be exacerbating existing healthcare disparities, creating additional obstacles for already vulnerable populations.
Impact on Patient Healthcare Utilization
Emergency Department Visits Increase
One of the most significant findings from the research was the direct connection between insurance denials and emergency healthcare use. Patients with a history of payer blocking were significantly more likely to visit the emergency department for migraine-related issues. This pattern creates a costly paradox: insurance companies attempting to control costs through medication restrictions may actually be driving patients toward more expensive emergency care.
Hospitalization Rates Rise
Beyond emergency department visits, the study found that patients facing repeated insurance denials were also more likely to be hospitalized for both migraine-related and other health issues. This suggests that inadequate migraine management due to medication access barriers may have cascading effects on overall health status, leading to more severe complications requiring inpatient care.
“When one in five patients faces repeated denials for prescribed medications, the result is more emergency visits, hospitalizations, and suffering,” explained Dr. Dawn C. Buse, lead author and clinical professor of neurology at Albert Einstein College of Medicine. “These insurance barriers don’t just delay care — they undermine quality of life, especially for those with fewer resources. Reducing them is essential to improving migraine outcomes.”
Understanding Payer Blocking Strategies
What is Payer Blocking?
The Headache & Migraine Policy Forum defined “payer blocking” specifically for this study as two or more denials related to step therapy, prior authorization, or similar restrictions. This definition captures the pattern of repeated obstacles that patients face when trying to access prescribed medications, rather than isolated administrative issues.
Step Therapy and Prior Authorization
Step therapy requirements force patients to try and fail with less expensive medications before insurance will cover prescribed treatments, even when those treatments weren’t developed specifically for migraine. Prior authorization adds administrative burdens, requiring healthcare providers to obtain insurance approval before prescribing certain medications. These processes create delays in treatment initiation and often require patients to endure ineffective therapies before accessing appropriate care.
CGRP Therapies: Effective but Restricted
Clinical Guidelines vs. Real-World Access
“The good news is that migraine treatments have never been better, with CGRP-targeted therapies proving highly effective and well tolerated,” stated Dr. Richard B. Lipton, study author and professor and vice chair of neurology at the Albert Einstein College of Medicine. “Yet this study shows a clear gap between clinical guidelines and real-world access, as insurance barriers continue to delay or block these recommended treatments.”
Currently, all preventive medications developed specifically for migraine are branded products with no generic versions available. This reality creates particular challenges for insurance coverage, as payers often prefer generic alternatives regardless of clinical appropriateness.
First-Line Treatment Recommendations
The urgency of addressing insurance barriers is underscored by a recent position statement from the American Headache Society, which supports calcitonin gene-related peptide (CGRP) targeting therapies as first-line options for migraine prevention. This expert consensus represents current best practices in migraine management. However, payer blocking often forces patients to be failed by preventive treatments that were not developed for migraine before accessing these evidence-based therapies.
Call for Policy Reform
“These findings confirm what patients and providers have long understood: payer blocking strategies are real obstacles to timely, effective care,” said Kristen Santiago, executive director of The Headache & Migraine Policy Forum. “When one in five people with migraine faces delays or denials for proven treatment, the result is more emergency visits, higher costs, and unnecessary suffering.”
The study’s findings make a compelling case for policy reform to align insurance coverage with clinical guidelines and reduce barriers to effective migraine treatment. Addressing these insurance restrictions could simultaneously improve patient outcomes and potentially reduce overall healthcare costs by preventing emergency department visits and hospitalizations.
